In NF1-associated MPNSTs, RTK activation often coexists with the loss of canonical tumor suppressors (such as NF1, TP53, and CDKN2A), generating a synergistic effect that drives cell-autonomous mitogenic signaling and enhances tumor progression. The gene discussed is TP53; the disease is neoplasm.